# KN046 in Patients With Advanced Non-small Cell Lung Cancer

> **NCT03838848** · PHASE2 · TERMINATED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 120 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** KN046
- **DRUG:** KN046
- **DRUG:** KN046
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Ningetinib

## Key facts

- **NCT ID:** NCT03838848
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-05
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical benefit at the SMC meeting and decided to terminate enrollment.
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838848, "KN046 in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03838848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*